Nutritional Outlook

Nutritional Outlook, May 2018

Issue link: http://dc.cn.ubm-us.com/i/979319

Contents of this Issue

Navigation

Page 46 of 73

• Prop 65 compliance ^ independently verified 1 • Significant improvement in body composition 2 • Significant reduction in carbohydrate cravings and appetite 3 • Significant reduction in caloric intake 4 Additional claims available supporting: Energy • Mood • Metabolism • Cognition • Lean Body Mass ^Proposition 65 compliance independently verified for arsenic, cadmium, hexavalent chromium, lead, and mercury levels. † In subjects with atypical depression and high carbohydrate cravings. ** In healthy, overweight, adult women with carbohydrate cravings. ©2017 Nutrition 21, LLC. Chromax ® is a registered trademark of Nutrition 21, LLC. 1. Data on file 2017, Nutrition 21, LLC. 2. Kaats et al., Current Therapeutic Research 1998. 3. Docherty et al., Journal of Psychiatric Practice 2005; 11(5):302-14. 4. Anton et al., Diabetes Technology & Therapeutics 2008; 10(5):405-12. DRA1176102317 Not All Chromium is the Same * These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Learn more at Nutrition21.com or email info@nutrition21.com. Chromax ® from Nutrition 21— Not all chromium is the same. ® Improvement in Reduction of Symptom Scores Superior Reduction in Daily Calorie Intake Chromax ¨ dosed at 600 mcg chromium per day HAM-D Item Scores 0 -.2 -.4 -.6 -.8 -1 -1.2 -1.4 Appetite Eating Carbohydrate Craving *p<0.05 * * * Weeks 0 -50 -100 -150 -200 -250 -300 -350 -400 Kcal/day 0 1 2 3 4 5 6 7 8 *p<0.05 * Q Chromax ¨ Placebo Q Average caloric intake reduced by 374 calories per day 4** More than 2x reduction in carbohydrate cravings and 1.8x reduction in appetite vs. placebo 3† Baseline Kcal/day, Chromax ¨ =~1,500, Placebo=~1,800; Chromax ¨ dosed at 1000 mcg chromium per day

Articles in this issue

Links on this page

Archives of this issue

view archives of Nutritional Outlook - Nutritional Outlook, May 2018